OssDesign's Catalyst nanosynthetic bone graft was used in its 5,000th U.S. patient, the medtech company said May 30.
Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusions and is made of a proprietary nanocrystalline structure that's reabsorbed and replaced by new tissue, according to a news release. A study in Biomedical Journal of Scientific & Technical Research found Catalyst had a 93% spinal fusion rate and improvements in quality of life and pain after surgery.
The bone graft was launched in August 2021 and reached 1,000 patients in May 2023.